Home » Analysts’ Upgrades
Range Resources Upgraded by Zacks Investment Research (RRC)
Range Resources (NYSE: RRC) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating in a research note issued to investors on Tuesday. They currently have a $67.00 price target on the stock.
Zacks’ analyst wrote, “We are upgrading our recommendation on Range Resources to Neutral from Underperform, following solid fourth quarter...
GeoResources Shares Upgraded by Sidoti to “Buy” (GEOI)
GeoResources (NASDAQ: GEOI) was upgraded by investment analysts at Sidoti from a “neutral” rating to a “buy” rating in a note issued to investors on Tuesday.
Separately, analysts at Zacks Investment Research downgraded shares of GeoResources from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, February 9th. Analysts...
TAM S.A. Shares Upgraded to “Outperform” by Zacks Investment Research Analysts. (TAM)
TAM S.A. (NYSE: TAM) was upgraded by Zacks Investment Research from a “neutral” rating to an “outperform” rating in a note issued to investors on Tuesday. They currently have a $28.00 price target on the stock.
Zacks’ analyst wrote, “We upgrade our recommendation on TAM from Neutral to Outperform. The company foresees a strong and growing market in 2012 and hence...
Zacks Investment Research Analysts Upgrade Avon Products Shares to “Neutral” (AVP)
Avon Products (NYSE: AVP) was upgraded by Zacks Investment Research from an “underperform” rating to a “neutral” rating in a research note issued to investors on Tuesday. They currently have a $20.00 price target on the stock.
Zacks’ analyst wrote, “Avon’s fourth-quarter 2011 earnings of $0.39 per share missed the Zacks Consensus Estimate of $0.51 and dipped...
Manning & Napier Shares Upgraded to “Outperform” by Keefe, Bruyette & Woods Analysts. (MN)
Manning & Napier (NYSE: MN) was upgraded by analysts at Keefe, Bruyette & Woods to an “outperform” rating in a research report issued to clients and investors on Tuesday.
Separately, analysts at Keefe, Bruyette & Woods, Inc upgraded shares of Manning & Napier from a “market perform” rating to an “outperform” rating in a research note to investors...
Manning & Napier Shares Upgraded by Keefe, Bruyette & Woods, Inc to “Outperform” (MN)
Manning & Napier (NYSE: MN) was upgraded by equities research analysts at Keefe, Bruyette & Woods, Inc from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday.
Separately, analysts at Needham & Company raised their price target on shares of Manning & Napier from $15.00 to $16.00 in a research note to investors...
KiOR Upgraded by ThinkEquity to “Buy” (KIOR)
KiOR (NASDAQ: KIOR) was upgraded by equities research analysts at ThinkEquity from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.
Separately, analysts at UBS AG (NYSE: UBS) cut their price target on shares of KiOR from $28.00 to $25.00 in a research note to investors on Tuesday, January 31st. They now have a “buy” rating on the...
Tyson Foods Shares Upgraded to “Buy” by Davenport Analysts. (TSN)
Tyson Foods (NYSE: TSN) was upgraded by Davenport from a “neutral” rating to a “buy” rating in a research note issued on Tuesday.
Separately, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Tyson Foods in a research note to investors on Friday, February 24th. They now have a $20.00 price target on the stock. Analysts at BMO Capital...
Sidoti Analysts Upgrade Rollins Shares to “Buy” (ROL)
Rollins (NYSE: ROL) was upgraded by analysts at Sidoti from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.
Separately, analysts at Zacks Investment Research downgraded shares of Rollins from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, January 27th.
Rollins,...
Lifepoint Hospitals Shares Upgraded by Credit Suisse to “Neutral” (LPNT)
Lifepoint Hospitals (NASDAQ: LPNT) was upgraded by analysts at Credit Suisse (NYSE: CS) from an “underperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday.
Separately, analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Lifepoint Hospitals from $41.00 to $45.00 in a research note to investors on Wednesday,...


